Medication Non-Adherence
Conditions
Keywords
Integrated program on adherence using counseling, support services including cost-sharing where appropriate and educational materials mailed monthly.
Brief summary
Despite extensive reports of the benefits of statins in reducing serious cardiovascular events such as stroke and heart disease in patients with elevated LDL-cholesterol, patients do not take their medicines regularly as prescribed. Reasons include forgetfulness, lack of understanding of the seriousness of the disease, and fear of side effects. An intervention strategy comprising 3-5 minutes of counseling, emotional support and cost-sharing may be motivational and improve adherence to treatment.
Interventions
BEHAVIORALNo Patient Counseling
Patients do not receive any adherence counseling, or other patient support services
BEHAVIORALAdherence Counseling
Patients receive 3-5 minutes of adherence counseling, and other patient support services
Sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female aged \>21 years * Have received a new or re-fil prescription for atorvastatin at first study visit to Prairie Heart Institute * Signed informed consent
Exclusion criteria
* Unwilling to give written informed consent * Failed statin treatment in the past * Switched from another statin to atorvastatin because of co-pay program * Participated in an earlier Market Research study on Impact of cholesterol management behaviors post in-clinic adherence intervention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of Days Covered (PDC) | 180 days |
Secondary
| Measure | Time frame |
|---|---|
| Medication Possession Ratio (MPR) | 180 days |
| Persistence-the number of continuous days a patient is supplied with medication using the allowable grace period or gap (30 or 60 days). | 180 days |
| Percent of patients that are at least 80% adherent (PDC>0.8) | 180 days |
| Percent of patients who fill at least one atorvastatin prescription during the period of study | 180 days |
Countries
United States
Outcome results
None listed